Buprenorphine Induction for Fentanyl Dependent Opioid Users
Status:
Not yet recruiting
Trial end date:
2022-01-15
Target enrollment:
Participant gender:
Summary
The overall goal of this pilot study is to characterize illicit fentanyl and combination
fentanyl and opioid dependence explicitly, by assessing physiologic barriers to effective
buprenorphine induction. Results from this pilot study may make a case for a larger
feasibility study to be conducted through the Clinical Trials Network at the National
Institutes of Drug Abuse.
The primary hypothesis is that individuals dependent on illicit fentanyl and combination
fentanyl and opioids will have difficulty with standard buprenorphine induction, and will
need a modified approach. The primary outcome measure will be retention on buprenorphine at
seven days post induction. The secondary outcome measures will be objective precipitated
withdrawal and the rate of patients requiring or requesting to initiate methadone due to
intolerance of buprenorphine.
Phase:
Early Phase 1
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone